Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Clinical manifestations and diagnosis of the thalassemias

Topic Outline

GRAPHICS

INTRODUCTION

The major hemoglobin in adults is hemoglobin A, a tetramer consisting of one pair of alpha globin chains and one pair of beta globin chains. In normal subjects, globin chain synthesis is very tightly controlled, such that the ratio of production of alpha to non-alpha chains is 1.00 ± 0.05. Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one or more globin chains, thus disrupting this closely regulated ratio. (See "Molecular pathology of the thalassemic syndromes".)

The vast majority of adult patients with alpha or beta thalassemia minor are asymptomatic and may be diagnosed because of the presence of microcytic, hypochromic red cells, with or without minor degrees of anemia.

Thalassemias of intermediate degrees of severity (thalassemia intermedia) are common throughout the world, and may be due to the presence of more than one hemoglobin mutation in the same patient (eg, sickle cell thalassemia, hemoglobin E/beta thalassemia) or to the presence of an abnormal hemoglobin with a reduced (ie, thalassemic) production rate (eg, hemoglobin Lepore, hemoglobin Constant Spring).

Beta thalassemia major and alpha thalassemia major are on the other end of this spectrum. The former is associated with life-long transfusion-dependent anemia, while the latter is incompatible with extra-uterine life.

The clinical manifestations and diagnosis of the thalassemias will be reviewed here [1]. The management of beta thalassemia is discussed separately. (See "Treatment of beta thalassemia" and "Efficacy of hematopoietic cell transplantation in beta thalassemia major".)

                                                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Sep 17, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Martin A, Thompson AA. Thalassemias. Pediatr Clin North Am 2013; 60:1383.
  2. Forget BG. Thalassemia syndromes. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.485.
  3. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341:99.
  4. Adams JG 3rd, Coleman MB. Structural hemoglobin variants that produce the phenotype of thalassemia. Semin Hematol 1990; 27:229.
  5. Forget BG, Pearson HA. Hemoglobin synthesis and the thalassemias. In: Blood: Principles and Practice of Hematology, Handin RI, Lux SE, Stoesel TP (Eds), JB Lippincott, Philadelphia 1995. p.1525.
  6. Schwartz E, Benz EJ Jr. Thalassemia syndromes. In: Smith's Blood Diseases of Infancy and Childhood, 6th ed, Miller DR, Baehner RL (Eds), CV Mosby, St. Louis 1989. p.428.
  7. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6:226.
  8. Rahav G, Volach V, Shapiro M, et al. Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol 2006; 133:667.
  9. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood 2004; 104:34.
  10. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353:1135.
  11. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110:971.
  12. Basu S, Kumar A. Hair-on-end appearance in radiograph of skull and facial bones in a case of beta thalassaemia. Br J Haematol 2009; 144:807.
  13. Haidar R, Mhaidli H, Musallam KM, Taher AT. The spine in β-thalassemia syndromes. Spine (Phila Pa 1976) 2012; 37:334.
  14. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci 1998; 850:344.
  15. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003; 123:730.
  16. Engkakul P, Mahachoklertwattana P, Jaovisidha S, et al. Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 2013; 35:212.
  17. Perrotta S, Cappellini MD, Bertoldo F, et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000; 111:461.
  18. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, et al. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000; 111:902.
  19. Ferrara M, Matarese SM, Francese M, et al. Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 2002; 117:436.
  20. Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112:36.
  21. Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol 2003; 120:353.
  22. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Clin Endocrinol (Oxf) 1995; 42:581.
  23. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127:127.
  24. Tsay J, Yang Z, Ross FP, et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood 2010; 116:2582.
  25. Chan YL, Li CK, Pang LM, Chik KW. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth. Clin Radiol 2000; 55:610.
  26. Naselli A, Vignolo M, Di Battista E, et al. Long-term follow-up of skeletal dysplasia in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11 Suppl 3:817.
  27. Fung EB, Kwiatkowski JL, Huang JN, et al. Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2013; 98:960.
  28. Bekheirnia MR, Shamshirsaz AA, Kamgar M, et al. Serum zinc and its relation to bone mineral density in beta-thalassemic adolescents. Biol Trace Elem Res 2004; 97:215.
  29. Mutlu M, Argun M, Kilic E, et al. Magnesium, zinc and copper status in osteoporotic, osteopenic and normal post-menopausal women. J Int Med Res 2007; 35:692.
  30. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood 2005; 105:4103.
  31. Weizer-Stern O, Adamsky K, Amariglio N, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol 2006; 135:129.
  32. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13:1096.
  33. Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124:114.
  34. Premawardhena A, Fisher CA, Fathiu F, et al. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. Lancet 2001; 357:1945.
  35. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111:467.
  36. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99:36.
  37. Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8:54.
  38. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574.
  39. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2012; 87:167.
  40. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 2009; 146:546.
  41. Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012; 87:155.
  42. Farmaki K, Angelopoulos N, Anagnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006; 134:438.
  43. Pepe A, Meloni A, Rossi G, et al. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br J Haematol 2013; 163:520.
  44. Kremastinos DT, Tsetsos GA, Tsiapras DP, et al. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001; 111:349.
  45. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-thalassemia syndromes: a decade of progress. Am J Med 2005; 118:957.
  46. Hahalis G, Manolis AS, Gerasimidou I, et al. Right ventricular diastolic function in beta-thalassemia major: echocardiographic and clinical correlates. Am Heart J 2001; 141:428.
  47. Detterich J, Noetzli L, Dorey F, et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol 2012; 87:139.
  48. Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013; 128:281.
  49. Kostopoulou AG, Tsiapras DP, Chaidaroglou AS, et al. The pathophysiological relationship and clinical significance of left atrial function and left ventricular diastolic dysfunction in β-thalassemia major. Am J Hematol 2014; 89:13.
  50. Detchaporn P, Kukongviriyapan U, Prawan A, et al. Altered vascular function, arterial stiffness, and antioxidant gene responses in pediatric thalassemia patients. Pediatr Cardiol 2012; 33:1054.
  51. Ferrara M, Matarese SM, Francese M, et al. Role of apolipoprotein E (APOE) polymorphism on left cardiac failure in homozygous beta thalassaemic patients. Br J Haematol 2001; 114:959.
  52. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14:55.
  53. Origa R, Satta S, Matta G, Galanello R. Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major. Br J Haematol 2008; 142:143.
  54. Wood JC, Claster S, Carson S, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol 2008; 141:891.
  55. Pepe A, Positano V, Capra M, et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart 2009; 95:1688.
  56. Piga A, Longo F, Musallam KM, et al. Left ventricular noncompaction in patients with β-thalassemia: uncovering a previously unrecognized abnormality. Am J Hematol 2012; 87:1079.
  57. Sohn EY, Kato R, Noetzli LJ, et al. Exercise performance in thalassemia major: correlation with cardiac iron burden. Am J Hematol 2013; 88:193.
  58. Hahalis G, Manolis AS, Apostolopoulos D, et al. Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J 2002; 23:147.
  59. Hershko C, Cappellini MD, Galanello R, et al. Purging iron from the heart. Br J Haematol 2004; 125:545.
  60. Carpenter JP, Roughton M, Pennell DJ, Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica 2013; 98:1368.
  61. Origa R, Danjou F, Cossa S, et al. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. Br J Haematol 2013; 163:400.
  62. Sohn EY, Noetzli LJ, Gera A, et al. Pulmonary function in thalassaemia major and its correlation with body iron stores. Br J Haematol 2011; 155:102.
  63. Tam DH, Farber HW. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. Am J Hematol 2006; 81:443.
  64. Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006; 81:670.
  65. Vij R, Machado RF. Pulmonary complications of hemoglobinopathies. Chest 2010; 138:973.
  66. Morris CR, Kim HY, Trachtenberg F, et al. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood 2011; 118:3794.
  67. Derchi G, Galanello R, Bina P, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation 2014; 129:338.
  68. Haines D, Martin M, Carson S, et al. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 2013; 160:680.
  69. Oliveros O, Trachtenberg F, Haines D, et al. Pain over time and its effects on life in thalassemia. Am J Hematol 2013; 88:939.
  70. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009; 122:155.
  71. Erdoğan E, Canatan D, Ormeci AR, et al. The effects of chelators on zinc levels in patients with thalassemia major. J Trace Elem Med Biol 2013; 27:109.
  72. Vatanavicharn S, Pringsulka P, Kritalugsana S, et al. Zinc and copper status in hemoglobin H disease and beta-thalassemia/hemoglobin E disease. Acta Haematol 1982; 68:317.
  73. Dragean CA, Duquesne L, Theate I, et al. Extramedullary haemopoiesis and spinal cord compression. Lancet 2011; 377:251.
  74. Danjou F, Anni F, Perseu L, et al. Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica 2012; 97:989.
  75. Tassiopoulos T, Rombos Y, Konstantopoulos K, et al. Spleen size in beta-thalassaemia heterozygotes. Haematologia (Budap) 1995; 26:205.
  76. Karimi M, Bagheri MH, Tahmtan M, et al. Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran. Eur J Radiol 2009; 69:120.
  77. Premawardhena A, Arambepola M, Katugaha N, Weatherall DJ. Is the beta thalassaemia trait of clinical importance? Br J Haematol 2008; 141:407.
  78. Sheiner E, Levy A, Yerushalmi R, Katz M. Beta-thalassemia minor during pregnancy. Obstet Gynecol 2004; 103:1273.
  79. Gallerani M, Scapoli C, Cicognani I, et al. Thalassaemia trait and myocardial infarction: low infarction incidence in male subjects confirmed. J Intern Med 1991; 230:109.
  80. Dentali F, Romualdi E, Ageno W, et al. Thalassemia trait and arterial thromboembolic events: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2011; 9:917.
  81. Maioli M, Pettinato S, Cherchi GM, et al. Plasma lipids in beta-thalassemia minor. Atherosclerosis 1989; 75:245.
  82. Tassiopoulos T, Stamatelos G, Zakopoulos N, et al. Low incidence of acute myocardial infarction in beta-thalassaemia trait carriers. Haematologia (Budap) 1995; 26:199.
  83. Verhovsek M, So CC, O'Shea T, et al. Is HbA2 level a reliable diagnostic measurement for β-thalassemia trait in people with iron deficiency? Am J Hematol 2012; 87:114.
  84. Passarello C, Giambona A, Cannata M, et al. Iron deficiency does not compromise the diagnosis of high HbA(2) β thalassemia trait. Haematologica 2012; 97:472.
  85. Kattamis C, Lagos P, Metaxotou-Mavromati A, Matsaniotis N. Serum iron and unsaturated iron-binding capacity in the -thalassaemia trait: their relation to the levels of haemoglobins A, A 2 , and F. J Med Genet 1972; 9:154.
  86. Fucharoen S, Fucharoen G, Sanchaisuriya K, Pengjam Y. Molecular analysis of a thai beta-thalassaemia heterozygote with normal haemoglobin A2 level: implication for population screening. Ann Clin Biochem 2002; 39:44.
  87. Galanello R, Barella S, Ideo A, et al. Genotype of subjects with borderline hemoglobin A2 levels: implication for beta-thalassemia carrier screening. Am J Hematol 1994; 46:79.
  88. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97:3411.
  89. Chang YP, Littera R, Garau R, et al. The role of heterocellular hereditary persistence of fetal haemoglobin in beta(0)-thalassaemia intermedia. Br J Haematol 2001; 114:899.
  90. Maakaron JE, Musallam KM, Ayache JB, et al. A liver mass in an iron-overloaded thalassaemia intermedia patient. Br J Haematol 2013; 161:1.
  91. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013; 98:833.
  92. Ricchi P, Ammirabile M, Spasiano A, et al. Unexpected prevalence of hyperprolactinaemia associated with microprolactinoma and empty sella in a cohort of adult patients with non-transfusion-dependent thalassaemia: a prospective study. Br J Haematol 2014; 164:743.
  93. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol 2010; 150:486.
  94. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011; 96:1605.
  95. Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. Blood 2014; 124:803.
  96. Musallam KM, Sankaran VG, Cappellini MD, et al. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 2012; 119:364.
  97. Steinberg MH, Benz EJ Jr. Pathobiology of the human erythrocyte and its hemoglobins. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.356.
  98. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340:1021.
  99. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003; 101:791.
  100. Lorey F, Charoenkwan P, Witkowska HE, et al. Hb H hydrops foetalis syndrome: a case report and review of literature. Br J Haematol 2001; 115:72.
  101. Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med 2000; 343:544.
  102. Sheeran C, Weekes K, Shaw J, Pasricha SR. Complications of HbH disease in adulthood. Br J Haematol 2014; 167:136.
  103. Origa R, Sollaino MC, Giagu N, et al. Clinical and molecular analysis of haemoglobin H disease in Sardinia: haematological, obstetric and cardiac aspects in patients with different genotypes. Br J Haematol 2007; 136:326.
  104. Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 2006; 133:198.
  105. Pan LL, Eng HL, Kuo CY, et al. Usefulness of brilliant cresyl blue staining as an auxiliary method of screening for alpha-thalassemia. J Lab Clin Med 2005; 145:94.
  106. Lorey F, Cunningham G, Vichinsky EP, et al. Universal newborn screening for Hb H disease in California. Genet Test 2001; 5:93.
  107. Carr S, Rubin L, Dixon D, et al. Intrauterine therapy for homozygous alpha-thalassemia. Obstet Gynecol 1995; 85:876.
  108. Naqvi J, Marrow W, Nisbet-Brown E, et al. Normal development of an infant with homozygous alpha thalassemia (abstract). Blood 1997; 90(suppl 1):132a.
  109. Lee SY, Chow CB, Li CK, Chiu MC. Outcome of intensive care of homozygous alpha-thalassaemia without prior intra-uterine therapy. J Paediatr Child Health 2007; 43:546.
  110. Singer ST, Styles L, Bojanowski J, et al. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol 2000; 22:539.
  111. Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005; 116:e818.
  112. Lal A, Goldrich ML, Haines DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011; 364:710.
  113. Sutcharitchan P, Embury SH. Advances in molecular diagnosis of inherited hemoglobin disorders. Curr Opin Hematol 1996; 3:131.
  114. Orofino MG, Argiolu F, Sanna MA, et al. Fetal HLA typing in beta thalassaemia: implications for haemopoietic stem-cell transplantation. Lancet 2003; 362:41.